TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy
Science Advances · 2026
DOI: 10.1126/sciadv.aeb2465 ↗At a glance
Journal article in Science Advances, 2026. Written by Junbin Chen and 6 co-authors. Institution: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P. …. Major MEDLINE topics: Toll-Like Receptor 9, Cancer Vaccines, Azetidines, Cholesterol. Cited 2 times so far (Crossref); 44 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Key Research and Development-Program.
Abstract (original language)
Therapeutic cancer vaccines show great promise for de novo induction of antigen-specific T cell responses against tumors. However, weak coordination between innate immune activation and antigen delivery remains a major obstacle to vaccine efficacy. Here, we present a cholesterol azetidine derivative–assisted polymeric carrier, Aze-Chol NP, which stimulates innate immunity and primes tumor-specific CD8 + T cell responses. Mechanistically, Aze-Chol NP induces maturation and activation of dendritic cells (DCs) through the Toll-like receptor 9 (TLR9) pathway while simultaneously delivering protein or peptide antigens to DCs in lymph nodes. The Aze-Chol NP–based nanovaccines markedly inhibited tumor growth and prolonged survival in melanoma and human papillomavirus tumor models. Moreover, combining the nanovaccine with an anti–PD-L1 antibody produced a strong synergistic effect and long-term immune memory, achieving 80% survival beyond 100 days and complete rejection of tumor cell rechallenge. Overall, our study demonstrates that this TLR9-activating carrier provides an effective and straightforward strategy for developing potent cancer vaccines.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P. R. China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, and Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, Guangdong 510006, P. R.…
ORCID profiles: Junbin Chen, Miao Su, Mingda Yang, Xianzhu Yang, Jun Wang
Funding
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Key Research and Development-Program
Cite
APA
Chen, J., Su, M., Yu, B., Yang, M., Wang, H., Yang, X., & Wang, J. (2026). TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.aeb2465
Vancouver
Chen J, Su M, Yu B, Yang M, Wang H, Yang X, et al. TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy. Science Advances. 2026. doi:10.1126/sciadv.aeb2465
BibTeX
@article{Chen2026,
author = {Chen, Junbin and Su, Miao and Yu, Boya and Yang, Mingda and Wang, Huiye and Yang, Xianzhu and Wang, Jun},
title = {TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeb2465}
}
EUVIMED